-+ 0.00%
-+ 0.00%
-+ 0.00%

Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth

Barchart·08/26/2026 22:09:00
Listen to the news

Results Highlights for Interim Results ended 30 June 2026
Revenue reached RMB1,006.5 million, increasing by 21.0% YoY
Gross profit amounted to RMB341.7 million, increasing by 0.7% YoY
Gross profit margin was 34.0%

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.